Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 28, 2003. The report details specific corporate actions regarding share re-purchases and changes in directors' interests in the company's ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transactions:
- Share Re-purchase: 910,000 Ordinary 25 pence shares purchased for cancellation on February 27, 2003.
- Re-purchase Price: 1,092.88 pence per share.
- Trust Sale: The GSK Trust sold 3,141 Ordinary Shares at £11.02 per share.
- Trust Transfer: The GSK Trust transferred 3,752 Ordinary Shares to participants of the Glaxo Wellcome 1999 Long Term Incentive Plan.
Material Changes
The filing reports a reduction in the company's share count due to the cancellation of 910,000 shares. Additionally, there were minor adjustments in the holdings of the GlaxoSmithKline Employee Trust involving sales and transfers to plan participants. No material changes to the company's core business operations or financial position are detailed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The document is strictly a notification of share transactions and director interest changes.
Key Facts for Investor Verification
- Verify the total number of shares repurchased and cancelled under the authority granted at the May 20, 2002 Annual General Meeting.
- Confirm the impact of the 910,000 share cancellation on the total outstanding share count.
- Review the specific terms of the Glaxo Wellcome 1999 Long Term Incentive Plan regarding the transfer of 3,752 shares.
- Note that this filing does not contain quarterly or annual financial performance data.